Abisola Idu, MS, MPH

Abisola Idu

“I apply well-established and innovative statistical methods to clinical and public health research. My objective is to support, challenge, or capture new findings that influence decisions that can improve health and health care, worldwide."

Abisola Idu, MS, MPH

Collaborative Biostatistician I, Kaiser Permanente Washington Health Research Institute

Abisola.Idu@kp.org
206-287-2893

Biography

Biostatistician Abisola Idu, MS, MPH, is interested in research that investigates the effectiveness and efficacy of treatment in pharmacoepidemiologic studies. She has a broad range of interest in research with a strong motivation to investigate the health challenges of malaria, obesity, cancer, heart disease, and maternal health.

Ms. Idu began her contributions to clinical and public health research through her academic training at the University of Texas Health Science Center, School of Public Health. She further got rigorous research experience by being a part of the leukemia, lymphoma, and cancer prevention research team at The University of Texas M.D. Anderson Cancer Center in 2015. She has been a biostatistician at Kaiser Permanente Washington Health Research Institute's Biostatistics Unit since 2018.

Ms. Idu looks forward to using her expertise in application of epidemiological principles and surveillance methodologies at KPWHRI. She has an in-depth knowledge of the ICH-GCP, FDA, IRB policies, regulations, and guidelines and plans to use her skills and background to implement epidemiologic study designs in clinical research studies.

Research interests and experience

  • Cancer

    Efficacy and safety of therapies; association between genetic variability and survival outcomes

  • Obesity 

    Role of nutritional, psychological and lifestyle factors; obesity prevention and control

  • Heart Disease

    Role of aging, nutritional and lifestyle factors; Intervention strategies for prevention and disease control

  • Maternal Health

    Association between social, behavioral and clinical factors and maternal and infant outcomes

  • Malaria

    Malaria prevention and control; development of vaccines; availability and accessibility to malaria treatment

  • Women's Health

  • Mental Health

  • Biostatistics

  • Social Determinants of Health

  • Vaccines & Infectious Diseases

  • Cardiovascular Health

Recent publications

Wartko PD, Bobb JF, Boudreau DM, Matthews AG, McCormack J, Lee AK, Qiu H, Yu O, Hyun N, Idu AE, Campbell CI, Saxon AJ, Liu DS, Altschuler A, Samet JH, Labelle CT, Zare-Mehrjerdi M, Stotts AL, Braciszewski JM, Murphy MT, Dryden D, Arnsten JH, Cunningham CO, Horigian VE, Szapocznik J, Glass JE, Caldeiro RM, Phillips RC, Shea M, Bart G, Schwartz RP, McNeely J, Liebschutz JM, Tsui JI, Merrill JO, Lapham GT, Addis M, Bradley KA; PROUD Trial Collaborators; Ghiroli MM, Hamilton LK, Hu Y, LaHue JS, Loree AM, Murphy SM, Northrup TF, Shmueli-Blumberg D, Silva AJ, Weinstein ZM, Wong MT, Burganowski RP. Nurse care management for opioid use disorder treatment: The PROUD cluster randomized clinical trial. JAMA Intern Med. 2023 Oct 30:e235701. doi: 10.1001/jamainternmed.2023.5701. [Epub ahead of print]. PubMed

Glass JE, Dorsey CN, Beatty T, Bobb JF, Wong ES, Palazzo L, King D, Mogk J, Stefanik-Guizlo K, Idu A, Key D, Fortney JC, Thomas R, McWethy AG, Caldeiro RM, Bradley KA. Study protocol for a factorial-randomized controlled trial evaluating the implementation, costs, effectiveness, and sustainment of digital therapeutics for substance use disorder in primary care (DIGITS Trial).  Implement Sci. 2023 Feb 1;18(1):3. doi: 10.1186/s13012-022-01258-9. PubMed

Wartko PD, Qiu H, Idu AE, Yu O, McCormack J, Matthews AG, Bobb JF, Saxon AJ, Campbell CI, Liu D, Braciszewski JM, Murphy SM, Burganowski RP, Murphy MT, Horigian VE, Hamilton LK, Lee AK, Boudreau DM, Bradley KA. Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: comparison of trial and non-trial clinics in the same health systems. BMC Health Serv Res. 2022 Dec 29;22(1):1593. doi: 10.1186/s12913-022-08915-1. PubMed

Cheetham TC, Shortreed SM, Avalos LA, Reynolds K, Holt VL, Easterling TR, Portugal C, Zhou H, Neugebauer RS, Bider Z, Idu A, Dublin S. Identifying hypertensive disorders of pregnancy, a comparison of two epidemiologic definitions.  Front Cardiovasc Med. 2022 Nov 23;9:1006104. doi: 10.3389/fcvm.2022.1006104. eCollection 2022.  PubMed

Coley RY, Smith JJ, Karliner L, Idu AE, Lee SJ, Fuller S, Lam R, Barnes DE, Dublin S. External validation of the eRADAR risk score for detecting undiagnosed dementia in two real-world healthcare systems. J Gen Intern Med. 2022 Jul 29. doi: 10.1007/s11606-022-07736-6. Online ahead of print. PubMed

Braciszewski JM, Idu AE, Yarborough BJH, Stumbo SP, Bobb JF, Bradley KA, Rossom RC, Murphy MT, Binswanger IA, Campbell CI, Glass JE, Matson TE, Lapham GT, Loree AM, Barbosa-Leiker C, Hatch MA, Tsui JI, Arnsten JH, Stotts A, Horigian V, Hutcheson R, Bart G, Saxon AJ, Thakral M, Ling Grant D, Pflugeisen CM, Usaga I, Madziwa LT, Silva A, Boudreau DM. Sex differences in comorbid mental and substance use disorders among primary care patients with opioid use disorder. Psychiatr Serv. 2022 Jun 16:appips202100665. doi: 10.1176/appi.ps.202100665. Online ahead of print. PubMed

 

Research

PROUD_trial_1col.jpg

Increasing opioid use disorder treatment in primary care

A trial led by KPWHRI researchers found that adding nurse care managers helped more people get needed treatment.

Research

Female doctor and senior female patient sitting around desk

Dementia risk screening tool shows promise

In a new study, a tool to help discover undiagnosed dementia performed well in 2 separate health systems.

Research

Hypertension-in-pregnancy_1col.jpg

New findings on treating hypertension in pregnancy

A study led by Dr. Sascha Dublin finds similar outcomes for 3 hypertension medications, filling an evidence gap.

COVID-19

Shortreed-COVID-19-disparities-paper_1col.jpg

Greater infection risks linked to COVID-19 disparities

New work by Susan Shortreed, PhD, finds infection risks drive worse outcomes for some racial and ethnic groups.